ArticleFrontiers in pharmacology2026
Study on the mechanism of action of Kangfuxin liquid in alleviating DSS-induced ulcerative colitis in mice.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we investigated the potential regulatory mechanisms of KFX on Dextran Sulfate Sodium Salt (DSS)-induced UC in mice by 16 S rRNA gene sequencing and metabolomics analysis of colonic contents. Differentially expressed metabolites and metabolic pathways were detected using a colon contents metabolomics-based approach. 16 S rRNA gene sequencing was used to assess changes in gut microbes at the genus level and for functional prediction. Results revealed metabolic disturbances in UC mice associated with 33 bacterial genera and 70 metabolites in the gut. Collectively, these findings suggest that UC is associated with metabolic disorders and microbial dysbiosis. Further, our data indicate that KFX administration is accompanied by significant alterations in intestinal flora composition and metabolic profiles, which may contribute to its protective effects against UC. However, the causal relationships between these microbial and metabolic changes and the therapeutic effects of KFX remain to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.